Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

Trial Profile

Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Bimatoprost/timolol (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions
  • Sponsors Allergan
  • Most Recent Events

    • 15 Mar 2017 Planned End Date changed from 1 Sep 2018 to 1 Mar 2018.
    • 15 Mar 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2018.
    • 30 Jan 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top